<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01267058</url>
  </required_header>
  <id_info>
    <org_study_id>263855/002</org_study_id>
    <nct_id>NCT01267058</nct_id>
  </id_info>
  <brief_title>Booster Study of Combined Diphtheria-tetanus-acellular Pertussis Vaccine in Healthy Adults</brief_title>
  <official_title>Single-blind, Clinical Study of the Immunogenicity and Reactogenicity of SB Biologicals' dTpa, pa Vaccines and a Td Vaccine, Given as a Booster Dose to Healthy Adults, From the Age of 18 Years Onwards</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the safety and immunogenicity of GlaxoSmithKline
      Biologicals' (formerly known as SmithKline Beecham Biologicals) combined
      diphtheria-tetanus-acellular pertussis vaccine in healthy adults, from the age of 18 onwards,
      in Australia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 1997</start_date>
  <completion_date type="Actual">February 1998</completion_date>
  <primary_completion_date type="Actual">February 1998</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of solicited local and general symptoms</measure>
    <time_frame>Within the 15-day (Day 0 - Day 14) follow-up period after the first injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity with respect to components of the study vaccines</measure>
    <time_frame>One month after the first injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity with respect to components of the study vaccines</measure>
    <time_frame>One month after the second injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of solicited local symptoms and fever</measure>
    <time_frame>Within the 15-day (Day 0 - Day 14) follow-up period after the second injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of general solicited symptoms to vaccination, other than fever</measure>
    <time_frame>Within the 15-day (Day 0 - Day 14) follow-up period after each vaccine administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of unsolicited symptoms</measure>
    <time_frame>Within 31 days (Day 0 - Day 30) after each vaccine administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of serious adverse experiences to vaccination</measure>
    <time_frame>Within 31 days (Day 0 - Day 30) after each vaccine administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity with respect to components of the study vaccines</measure>
    <time_frame>Immediately prior to the booster vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity with respect to components of the study vaccines</measure>
    <time_frame>One year after the vaccination in a subset of subjects from all the groups</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity with respect to components of the study vaccines</measure>
    <time_frame>2, 3, 4 and 5 years after the vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">550</enrollment>
  <condition>Diphtheria</condition>
  <condition>Pertussis</condition>
  <condition>Tetanus</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive the combined diphtheria, tetanus, acellular pertussis vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive the acellular pertussis vaccine and one month later the combined diphtheria and tetanus vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive the combined diphtheria and tetanus vaccine and one month later the acellular pertussis vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' combined diphtheria, tetanus, acellular pertussis vaccine</intervention_name>
    <description>Intramuscular, single dose</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' acellular pertussis vaccine</intervention_name>
    <description>Intramuscular, single dose</description>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Commonwealth Serum Laboratories' combined diphtheria and tetanus vaccine</intervention_name>
    <description>Intramuscular, single dose</description>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age at the time of the vaccination

          -  Written informed consent has been obtained

        Exclusion Criteria:

          -  Evidence of confirmed pertussis disease within the previous 5 years

          -  History of diphtheria or tetanus vaccination within the past 5 years Females must not
             be pregnant or lactating They must either surgically sterilized or one year
             post-menopausal or if they are of childbearing potential, they must be abstinent or
             have used adequate contraceptive precautions (or one month prior to the booster
             vaccination, and must agree to continue such precautions for 2 months after completion
             of the vaccination.

          -  History of diphtheria or tetanus disease

          -  History of allergic disease likely to be stimulated by the vaccination

          -  Major congenital defects or serious chronic illness

          -  History of progressive neurological disease

          -  Immunosuppressive therapy

          -  Any suspected or confirmed immune disorder

          -  Immunoglobulin therapy or administration of any blood products within the previous
             three months or during the study period

          -  Acute febrile illness (&gt;37.5°C, axillary or oral temperature) at the time of planned
             vaccination

          -  Administration of an investigational or non registered drug or vaccine within 30 days
             prior to the start of the present trial

          -  Simultaneous administration of a vaccine not foreseen by the study protocol, within 30
             days prior to the start of the present trial

          -  Any severe or serious adverse experience having occurred after previous administration
             of DTP vaccine i.e:

               -  an immediate anaphylactic or unacceptable reaction to the investigator's opinion,
                  to a previous dose of diphtheria tetanus pertussis whole-cell vaccine, i.e. :

               -  encephalopathy

               -  fever &gt; 40.5°C (105°F), rectal temperature, occurring after vaccination with
                  diphtheria tetanus pertussis whole-cell vaccine and not due to another
                  identifiable cause.

               -  collapse or shock-like state

               -  persistent, inconsolable crying lasting &gt; 3 hours

               -  seizures with or without fever

               -  systemic allergic or neurologic reactions following a previous dose of tetanus
                  and diphtheria toxoids vaccine

          -  Exclusion from long term follow-up of antibody persistence : Evidence of confirmed
             pertussis, diphtheria or tetanus disease or vaccination against these diseases since
             previous study visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <reference>
    <citation>Cheuvart B, Burgess M, Zepp F, Mertsola J, Wolter J, Schuerman L. Anti-diphtheria antibody seroprotection rates are similar 10 years after vaccination with dTpa or DTPa using a mathematical model. Vaccine. 2004 Dec 2;23(3):336-42.</citation>
    <PMID>15530678</PMID>
  </reference>
  <reference>
    <citation>Van Damme P, Burgess M. Immunogenicity of a combined diphtheria-tetanus-acellular pertussis vaccine in adults. Vaccine. 2004 Jan 2;22(3-4):305-8.</citation>
    <PMID>14670310</PMID>
  </reference>
  <reference>
    <citation>Turnbull FM, Heath TC, Jalaludin BB, Burgess MA, Ramalho AC. A randomized trial of two acellular pertussis vaccines (dTpa and pa) and a licensed diphtheria-tetanus vaccine (Td) in adults. Vaccine. 2000 Nov 8;19(6):628-36.</citation>
    <PMID>11090714</PMID>
  </reference>
  <results_reference>
    <citation>McIntyre PB, Burgess MA, Egan A, Schuerman L, Hoet B. Booster vaccination of adults with reduced-antigen-content diphtheria, Tetanus and pertussis vaccine: immunogenicity 5 years post-vaccination. Vaccine. 2009 Feb 11;27(7):1062-6. doi: 10.1016/j.vaccine.2008.11.102. Epub 2008 Dec 16.</citation>
    <PMID>19095033</PMID>
  </results_reference>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2010</study_first_submitted>
  <study_first_submitted_qc>December 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2010</study_first_posted>
  <last_update_submitted>December 23, 2010</last_update_submitted>
  <last_update_submitted_qc>December 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2010</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <keyword>Booster vaccination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

